|
|
|
|
Episodic Src activation in uveal melanoma revealed by kinase activity profiling
The RAS/RAF/MEK/ERK pathway is involved in the balance between melanocyte proliferation and differentiation.The same pathway is constitutively activated in cutaneous and uveal melanoma (UM) and related to tumour growth and survival....
|
|
|
Proton beam radiotherapy of uveal melanoma yields high rate of tumor control
Submit a Comment Irradiation of uveal tumors with a proton beam effectively controls tumor growth in the long term and results in high survival and eye retention rates, according to a study.Out of 368 cases treated for intraocular...
|
|
|
Effectiveness of Treatments for Metastatic Uveal Melanoma
(Click the title below to leave the MDLinx Network and go to the Journal's Website) American Journal of Ophthalmology, 06/26/09 Print Save in My Library Free Abstract Augsburger JJ et al.- Although median survival time after diagnosis of...
|
|
|
What Is Skin Cancer? What Is Melanoma?
Melanoma is a malignant tumor of melanocytes.The tumors are generally found in the skin, but may also appear in the bowel and the eye (uveal melanoma). Melanoma is a type of skin cancer - one of the rarer types - but the cause of...
|
|
|
Recognizing the 'White Dot' Syndromes
Inflammatory chorioretinopathies of unknown etiology, also called 'white dot syndromes' are common uveitic entities that affect relatively young, otherwise healthy, patients.These entities include: acute posterior multifocal placoid...
|
|
|
Limited value of 18F-FDG PET/CT and S-100B tumour marker in the detection of liver metastases from uveal melan
(Click the title below to leave the MDLinx Network and go to the Journal's Website) European Journal of Nuclear Medicine & Molecular Imaging, 06/08/09 Print Save in My Library Free Abstract Strobel K et al.- FDG PET/CT and serum S...
|
|
|
Resveratrol Investigated as Treatment for Neuroblastoma & Ocular/Uveal Melanoma
Resveratrol is being proposed for clinical trials against neuroblastoma.A team led by Arthur Polans, PhD, Professor of Ophthalmology and Visual Sciences at the University of Wisconsin School of Medicine and Public Health, part of the...
|
|
|
Hana Biosciences Presents Updated Marqibo Data At the American Society of Clinical Oncology Annual Meeting
* 30% CR/CRi Rate in First 33 rALLy Subjects * rALLy Study Expected to Reach Target Enrollment by Mid-Year * Encouraging Survival in Metastatic Uveal Melanoma Trial SOUTH SAN FRANCISCO, Calif., June 2, 2009 (GLOBE NEWSWIRE) -- Hana...
|
|
|
Hana Biosciences Presents Updated Marqibo Data At the American Society of Clinical Oncology Annual Meeting
* 30% CR/CRi Rate in First 33 rALLy Subjects * rALLy Study Expected to Reach Target Enrollment by Mid-Year * Encouraging Survival in Metastatic Uveal Melanoma Trial SOUTH SAN FRANCISCO, Calif., June 2, 2009 (GLOBE NEWSWIRE) -- Hana...
|
|
|
Hana Biosciences Presents Updated Marqibo Data At the American Society of Clinical Oncology Annual Meeting
* 30% CR/CRi Rate in First 33 rALLy Subjects * rALLy Study Expected to Reach Target Enrollment by Mid-Year * Encouraging Survival in Metastatic Uveal Melanoma Trial SOUTH SAN FRANCISCO, Calif., June 2, 2009 (GLOBE NEWSWIRE) -- Hana...
|
|
|
Hana Biosciences Presents Updated Marqibo Data At the American Society of Clinical Oncology Annual M
* 30% CR/CRi Rate in First 33 rALLy Subjects * rALLy Study Expected to Reach Target Enrollment by Mid-Year * Encouraging Survival in Metastatic Uveal Melanoma Trial SOUTH SAN FRANCISCO, Calif., June 2, 2009 (GLOBE NEWSWIRE) -- Hana...
|
|
|
Hana Biosciences presents updated data of Marqibo for treatment of adult acute lymphoblastic leukemia in secon
AM ET RELATED NEWS TOP MARKET NEWS (RTTNews) - Hana Biosciences (HNAB: News ) presented updated data for Marqibo for the treatment of adult acute lymphoblastic leukemia in second relapse and data from metastatic uveal melanoma at the...
|
|
|
Hana Biosciences Presents Updated Marqibo Data At the American Society of Clinical Oncology Annual Meeting
(GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq: HNAB), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care, presented updated data for Marqibo(r) ...
|
|
|
Hana Biosciences Presents Updated Marqibo Data At the American Society of Clinical Oncology Annual Meeting
(GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care, presented updated data for Marqibo(r) ...
|
|
|
Eric D. Whitman, MD to Present on the Delcath PHP System at the 7th World Congress on Melanoma
NEW YORK, May 7 /PRNewswire-FirstCall/ -- Delcath Systems, Inc., ( (Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) Dr.Whitman's presentation, titled Percutaneous Isolated Hepatic Perfusion for Cutaneous and Uveal...
|
